You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Blueprint Medicines unveiled top-line data from its Phase I/II trial on pralsetinib (BLU-667) for the treatment of RET fusion-positive non-small cell lung cancer on Wednesday.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.